Full Press Release Details
Jazz Pharmaceuticals Announces FDA Acceptance and Priority Review of Supplemental Biologics License Application for Ziihera® (zanidatamab-hrii) Combinations in First-Line HER2+ Locally Advanced or Metastatic GEA.
ZYME
Jazz Pharmaceuticals Announces FDA Acceptance and Priority Review of Supplemental Biologics License Application for Ziihera® (zanidatamab-hrii) Combinations in First-Line HER2+ Locally Advanced or Metastatic GEA
Key Takeaway: Jazz Pharmaceuticals Announces FDA Acceptance and Priority Review of Supplemental Biologics License Application for Ziihera® (zanidatamab-hrii) Combinations in First-Line HER2+ Locally Advanced or Metastatic GEA
Price reaction · baseline $28.1 (2026-04-24 close) · 1 other ZYME headline(s) in the window, move may be shared
day 0 close · peak
+1.6%
BiopharmaWatch Analysis
From our catalyst data and publicly available data · not financial adviceBest trade, last catalyst
+25%
120-day peak, hindsight
Typical move
4.8%
average across 15 past catalysts
Cash runway
~28 mo
Minimal dilution risk
Lead asset
ZW49
Phase 1 · HER2-expressing Cancers